Oil-Adjuvanted Polyvalent Formalin-Killed Aeromonas hydrophila Vaccine Enhances Agglutinating Antibodies, Respiratory Burst, and Survival in Giant Gourami

Motile Aeromonas septicaemia (MAS), predominantly associated with Aeromonas hydrophila, remains a major constraint in giant gourami (Osphronemus goramy) aquaculture. This study evaluated formalin-inactivated A. hydrophila vaccines prepared from MAS-associated field isolates, comparing a monovalent f...

Full description

Saved in:
Bibliographic Details
Main Authors: Rozi, Tyasningsih, Wiwiek, Rahmahani, Jola, Aksono, Eduardus Bimo, Yunus, Muchammad, Arif, Mohammad Anam Al, Kuncorojakti, Suryo, Nindarwi, Daruti Dinda, Sari, Putri Desi Wulan, Dewi, Nina Nurmalia, Satyantini, Woro Hastuti, Santanumurti, Muhammad Browijoyo, Wisudyawati, Dita, Azmai, Mohammad Noor Amal, Salleh, Annas, Salim, Gazali, Suwarno
Format: Article
Language:en
Published: Faculty of Fisheries and Marine Universitas Airlangga 2026
Subjects:
Online Access:http://psasir.upm.edu.my/id/eprint/124926/1/124926.pdf
http://psasir.upm.edu.my/id/eprint/124926/
https://e-journal.unair.ac.id/JIPK/article/view/82866
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Motile Aeromonas septicaemia (MAS), predominantly associated with Aeromonas hydrophila, remains a major constraint in giant gourami (Osphronemus goramy) aquaculture. This study evaluated formalin-inactivated A. hydrophila vaccines prepared from MAS-associated field isolates, comparing a monovalent formulation (P2), a non-adjuvanted polyvalent formulation (P3), and an oil-adjuvanted polyvalent formulation (P4) against PBS controls (P1). A total of 240 fish were used (60 per treatment) and assigned to two parallel cohorts (immunology and survival/challenge). Immune endpoints (agglutinating titres, NBT activity, and splenic il-1β and ifn-γ transcription) were assessed on days 7, 14, 21, 35, and 42 post-vaccination. The survival cohort was challenged intraperitoneally at day 21 with a homologous A. hydrophila strain and monitored for 14 days post-challenge. Vaccination was clinically well tolerated and improved survival relative to controls, with P4 showing the highest protection (RPS 81.8%). Agglutinating titres differed by treatment and time; at the peak sampling point (day 35), mean titres in P4 were ~200-fold higher than in P1, and model contrasts indicated significant differences versus controls (p<0.001). Splenic il-1β and ifn-γ transcript levels were higher in vaccinated groups than in controls at later time points. These findings support further evaluation of an oil-adjuvanted polyvalent inactivated A. hydrophila vaccine for gourami, including dose optimisation, extended safety assessment, heterologous challenge, and field validation.